Abstract:Engineered nanomaterials (such as graphene oxide, GO) have shown great potential in biomedical applications as therapeutic and imaging agents. However, little is known about their potential transformations in biological settings, which may alter their physicochemical properties and consequently hinder their biomedical applications. Here, we show that GO undergoes a significant physicochemical transformation in two simulated human lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids (e.g., citrate and acetate) in the lung fluids cause the reduction of GO, which is mainly due to the conversion of epoxy and carbonyl groups to phenolic groups. This biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, the alterations that occur in Gamble’s solution enhance the layer-by-layer aggregation of GO, resulting in the precipitation of GO and a reduction in its interaction with cells, whereas the changes that occur in ALF lead to edge-to-edge aggregation of GO, thereby enhancing the adhesion of large sheet-like GO aggregates on the plasma membrane without cellular uptake. The varied interaction mechanisms with macrophages eventually induce different proinflammatory reactions. Experiments conducted in mice corroborated the morphological alterations of GO in a realistic lung microenvironment. Overall, the findings suggest that the biotransformation of nanomaterials may significantly alter their inherent properties and therefore affect their biosafety, such as the clearance of “worn-out” nanomaterials by immune cells, giving rise to potentially long-term side effects at the accumulation sites. Graphene-oxide particles inserted into the body for biomedical applications such as drug delivery or enhanced imaging can form aggregates over time with possible adverse effects on health, and show researchers in China. After the medical objectives have been achieved, the nanoparticles often remain inside the human body, but it is unclear what happens to them after long time periods in a biological environment. Sijin Liu from the Chinese Academy of Sciences in Beijing, Wei Chen from Nankai University in Tianjin, and their colleagues show that graphene-oxide nanoparticles undergo a physicochemical transformation in simulated human lung fluids, aggregating to form larger particles. This reduces their interaction with cells and inhibits cellular uptake, and can induce proinflammatory reactions. The results highlight the need to consider the biosafety of nanomaterials and their potential long-term side effects. GO can undergo significant physicochemical transformation in two simulated lung fluids–Gamble’s solution and artificial lysosomal fluid (ALF), as the organic acids in lung fluids cause reduction of GO. Biotransformation markedly inhibits the endocytosis of GO by scavenging macrophages. Notably, alterations in Gamble’s solution enhance the aggregation of GO in a layer-to-layer manner, resulting in GO precipitation and reduced interaction with cells, whereas changes in ALF lead to edge-to-edge aggregation of GO, enhancing the adhesion of large sheet-like GO aggregates on plasma membrane without cellular uptake.

Graphene Oxide Nanosheets Toxicity in Mice Is Dependent on Protein Corona Composition and Host Immunity

[Immunogenic and toxic effects of graphene oxide nanoparticles in mouse skeletal muscles and human red blood cells]

Protein Corona-Mediated Mitigation of Cytotoxicity of Graphene Oxide.

Biocompatibility of graphene oxide intravenously administrated in mice—effects of dose, size and exposure protocols

Size‐Dependent Pulmonary Impact of Thin Graphene Oxide Sheets in Mice: Toward Safe‐by‐Design

Reproductive toxicity of nanoscale graphene oxide in male mice

Altered immune cells in the liver and spleen of mice as a typical immune response to graphene oxide exposure

Distribution and Biocompatibility Studies of Graphene Oxide in Mice after Intravenous Administration

Protein corona reduced graphene oxide cytotoxicity by inhibiting endocytosis

Induction of chromosomal and DNA damage and histological alterations by graphene oxide nanoparticles in Swiss mice

Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1)

Toxicity of Graphene Oxide and Multi-Walled Carbon Nanotubes Against Human Cells and Zebrafish

Next-Generation Sequencing Reveals Differential Responses to Acute versus Long-Term Exposures to Graphene Oxide in Human Lung Cells

Nanotoxicity of different sizes of graphene (G) and graphene oxide (GO) in vitro and in vivo.

Graphene Oxide Significantly Inhibits Cell Growth at Sublethal Concentrations by Causing Extracellular Iron Deficiency.

Effects of the Surface Polarity of Nanomaterials on Their Interaction with Complement Protein Gc1q

Graphene Oxide Modulates B Cell Surface Phenotype and Impairs Immunoglobulin Secretion in Plasma Cell

Consecutive Evaluation of Graphene Oxide and Reduced Graphene Oxide Nanoplatelets Immunotoxicity on Monocytes

Dependence of Graphene Oxide (GO) Toxicity on Oxidation Level, Elemental Composition, and Size

Effect of graphene oxide on conformation and activity of catalase

The Biotransformation of Graphene Oxide in Lung Fluids Significantly Alters Its Inherent Properties and Bioactivities Toward Immune Cells